Andrew J. Peacock

Pulmonary Vascular Research Institute — United Kingdom

Medicine · Health Sciences

47h-index21.8kcitations145works7.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pulmonary Hypertension Research and Treatments(84), Cardiovascular Function and Risk Factors(20), Cardiovascular Issues in Pregnancy(14), Polymer crystallization and properties(13), Heart Failure Treatment and Management(12)

Publications144 total

Initial Combination Therapy with Macitentan and Tadalafil in Patients with Pulmonary Arterial Hypertension, with and without Cardiac Comorbidities
European Journal of Heart Failure·2024· 14 citedOpen Access
Effect of Macitentan in Pulmonary Arterial Hypertension and the Relationship Between Echocardiography and cMRI Variables: REPAIR Echocardiography Sub-study Results
Cardiology and Therapy·2024· 1 citedOpen Access
Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
Nature Communications·2022Open Access
Left ventricular dysfunction and intra-ventricular dyssynchrony in idiopathic pulmonary arterial hypertension
International Journal of Cardiology·2022· 11 citedOpen Access
Diagnosis of Rosai-Dorfman Disease by Upper Endoscopic Ultrasound–Guided Fine-Needle Biopsy
ACG Case Reports Journal·2022· 1 citedOpen Access
COMPARISON OF STANDARDIZED TREATMENT EFFECT SIZES FOR INVASIVE AND NON-INVASIVE ENDPOINTS IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM THE REPAIR STUDY
Journal of the American College of Cardiology·2021· 3 cited
The Right Heart
2021· 1 cited
Physiology of the Normal Pulmonary Circulation
Elsevier eBooks·2020
REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH)
2020
Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study
2020· 4 cited
P116 Effects of macitentan on right ventricular remodeling in pulmonary arterial hypertension – results from the REPAIR study interim analysis
2019· 1 cited
EFFECTS OF MACITENTAN ON RIGHT VENTRICULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE REPAIR STUDY INTERIM ANALYSIS
Journal of the American College of Cardiology·2019· 2 cited
Pulmonary hypertension in chronic lung disease and hypoxia
European Respiratory Journal·2018· 730 citedOpen Access
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
The Journal of Heart and Lung Transplantation·2018· 28 citedOpen Access
The Right Heart-Pulmonary Circulation Unit
Heart Failure Clinics·2018· 28 cited
Abstract 14753: Loss of Function ABCC8 Mutations Are Associated With Pulmonary Arterial Hypertension
Circulation·2017
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
Annals of the Rheumatic Diseases·2016· 174 citedOpen Access
Abstract 14413: Whole Genome Sequencing in Idiopathic and Familial Pulmonary Arterial Hypertension Reveals Causal Rare Coding and Non-coding Sequence Variation
2016
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
The Lancet Respiratory Medicine·2016· 71 cited
Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH
Respiratory Research·2016· 75 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Marius M. Hoeper(12), Nazzareno Galiè(10), Marc Humbert(10), Adam Torbicki(8), Joan Albert Barberà(8), Lewis J. Rubin(8), Gérald Simonneau(7), Joanna Pepke‐Żaba(7), Maurice Beghetti(6), Hossein Ardeschir Ghofrani(6), Walter Klepetko(6), Seán Gaine(6), Jean-Luc Vachiéry(5), Simon Gibbs(5), J. Simon R. Gibbs(5), Paul A. Corris(5), Gerry Coghlan(5), Robert Naeije(4), David G. Kiely(4), Martin Johnson(4)